All data are based on the daily closing price as of October 17, 2024
s
SanBio
4592.TSE
6.87 USD
-0.13
-1.86%
Overview
Last close
6.87 usd
Market cap
471.69M usd
52 week high
9.45 usd
52 week low
2.57 usd
Target price
7.55 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
3458.1885
Price/Book Value
45.6668
Enterprise Value
462.45M usd
EV/Revenue
3405.5195
EV/EBITDA
-9.0194
Key financials
Revenue TTM
153620.09 usd
Gross Profit TTM
2.99M usd
EBITDA TTM
-20.14M usd
Earnings per Share
-0.21 usd
Dividend
N/A usd
Total assets
23.60M usd
Net debt
-16.91M usd
About
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson's disease, spinal cord injury, and Alzheimer's disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.